AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$ABT

MCCOY JOHN A. JR. sold $3K of ABT

MCCOY JOHN A. JR. (VICE PRESIDENT AND CONTROLLER) sold 27 shares of ABBOTT LABORATORIES (ABT) at $109.54 on 2026-09-02.

Original reporting
SEC EDGAR · MCCOY JOHN A. JR.
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:14 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ABT
Neutral
high confidence
Mentioned
$ABT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ABTNeutralLow
01

Why it matters

The transaction is a routine sale with minimal market relevance.

02

Market read

Low relevance; no expected price movement.

03

What to watch

Potential upcoming earnings or corporate actions not disclosed.

Relevance 3/10Novelty 4/10Timing: filed today

Background

SEC Form 4 filing for Abbott Laboratories insider transaction.

Company-level read

Ticker impact

$ABTNeutralHigh confidence
Context

Form 4 shows VP John McCoy sold 27 shares for $2,958, reducing his stake to 24,549 shares.

Expected impact

No material impact expected.

Evidence & confidence

Sale size is trivial relative to market cap and insider ownership.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

Even small insider sells can signal concerns, but evidence is insufficient.

Key entities

  • company
    Abbott Laboratories

    US healthcare company (ticker ABT).

  • person
    John A. McCoy Jr.

    Vice President and Controller, insider.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ABT insider trading history →

Related articles

$ABTMedAI 9/10

Abbott Touts Favorable Outcomes In Cardiovascular Device Trials

Abbott Laboratories (ABT) presented positive clinical trial results for two cardiovascular devices at a conference. The Amulet 360 LAA Occluder showed 96.3% complete closure in patients, with low complication rates. The SonicForce System achieved 97% procedural success in treating calcified coronary arteries. ABT shares rose 2.55% to $108.91.

finance.yahoo.com
$ABTMedAI 8/10

More than 98% of study patients had no stroke of the most common kind or blood-clot complication for a year.

Abbott (NYSE: ABT) presented one-year results from the VERITAS study of its Amulet 360 LAA Occluder, showing 98% of patients had no stroke or blood-clot complications. The device aims to reduce stroke risk in atrial fibrillation patients. Over 99% of patients had no pericardial effusion requiring intervention, and 98% had no cardiovascular-related mortality. The Amulet 360 features enhanced design for better LAA closure.

stocktitan.net
$ABTMed

Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke

Abbott (NYSE: ABT) presented one-year data from the VERITAS study on its Amulet 360 LAA Occluder, showing 96.3% closure rates and low stroke incidence in atrial fibrillation patients. The device is designed to reduce stroke risk and is approved for investigational use in the U.S. and CE Mark in Europe.

prnewswire.com
$ABTMedAI 8/10

Scans found heart-artery calcium fractures after an investigational sound-wave treatment

Abbott's investigational SonicForce Coronary IVL System showed positive results in the TECTONIC study, meeting safety and effectiveness endpoints. The study enrolled 335 patients with severe coronary calcification, reporting a 0.3% 30-day target lesion failure rate and 97% procedural success. The system uses acoustic pressure waves to crack calcium buildup in coronary arteries, potentially expanding Abbott's cardiovascular portfolio.

stocktitan.net
$ABTMedAI 9/10

Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System

Abbott (NYSE: ABT) reported positive 30-day results from its TECTONIC study of the investigational SonicForce Coronary IVL System, which met safety and effectiveness endpoints. The study showed a 0.3% target lesion failure rate and 97% procedural success in treating severe coronary calcification. The system uses acoustic pressure waves to crack calcium buildup in arteries, potentially expanding Abbott's portfolio of cardiovascular devices.

prnewswire.com